Wirkstoffe & Arzneimittelsicherheit

Wechselwirkungen · Reyataz

REYATAZ 50 mg oral powder · Abschnitt 4.5 · PDF-Seite 47–48

HOS-112173 · Präparat HOS-093615

47 Medicinal products by Interaction Recommendations therapeutic area concerning co-administration Tenofovir disoproxil Tenofovir disoproxil fumarate AUC: ↑37% Patients should be closely fumarate 300 mg once daily (↑30% ↑45%) monitored for tenofovir (atazanavir 300 mg once daily Tenofovir disoproxil fumarate Cmax: ↑34% disoproxil fumarate-associated with ritonavir 100 mg once (↑20% ↑51%) adverse reactions, including daily) Tenofovir disoproxil fumarate Cmin: ↑29% renal disorders. (↑21% ↑36%) 300 mg tenofovir disoproxil fumarate is equivalent to 245 mg tenofovir disoproxil. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) Efavirenz 600 mg once daily Atazanavir (pm): all administered with Co-administration of efavirenz (atazanavir 400 mg once daily food and REYATAZ is not with ritonavir 100 mg once Atazanavir AUC: ↔0%(↓9% ↑10%)* recommended (see daily) Atazanavir Cmax: ↑17%(↑8% ↑27%)* section 4.4). Atazanavir Cmin: ↓42%(↓51% ↓31%)* Efavirenz 600 mg once daily Atazanavir (pm): all administered with (atazanavir 400 mg once daily food with ritonavir 200 mg once Atazanavir AUC: ↔6% (↓10% ↑26%)*/** daily) Atazanavir Cmax: ↔9% (↓5% ↑26%)*/** Atazanavir Cmin: ↔12% (↓16% ↑49%)*/** *When compared to REYATAZ 300 mg/ritonavir 100 mg once daily in the evening without efavirenz. This decrease in atazanavir Cmin might negatively impact the efficacy of atazanavir. The mechanism of efavirenz/atazanavir interaction is CYP3A4 induction. **Based on historical comparison. Nevirapine 200 mg twice Nevirapine AUC: ↑26% (↑17% ↑36%) Co-administration of daily Nevirapine Cmax: ↑21% (↑11% ↑32%) nevirapine and REYATAZ is (atazanavir 400 mg once daily Nevirapine Cmin: ↑35% (↑25% ↑47%) not recommended (see with ritonavir 100 mg once section 4.4) daily) Atazanavir AUC: ↓19% (↓35% ↑2%)* Atazanavir Cmax: ↔2% (↓15% ↑24%)* Study conducted in Atazanavir Cmin: ↓59% (↓73% ↓40%)* HIV-infected patients. *When compared to REYATAZ 300 mg and ritonavir 100 mg without nevirapine. This decrease in atazanavir Cmin might negatively impact the efficacy of atazanavir. The mechanism of nevirapine/atazanavir interaction is CYP3A4 induction. Integrase Inhibitors Raltegravir 400 mg twice Raltegravir AUC: ↑41% No dose adjustment required daily Raltegravir Cmax: ↑24% for raltegravir. (atazanavir/ritonavir) Raltegravir C12hr: ↑77%

Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.

RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): tenofovir (HOS-088083) tenofovir disoproxil (HOS-108843) fumarate (HOS-108845) efavirenz (HOS-087947) tenofovir disoproxil fumarate (HOS-110471) raltegravir (HOS-086187) nevirapine (HOS-088064) ritonavir (HOS-084521)